Clinical Trial Update: A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 global trial is evaluating transarterial chemoembolization combined with durvalumab and bevacizumab for locoregional hepatocellular carcinoma; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING